Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene

EU orphan designation number: EU/3/10/768   
Active ingredient: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
Indication: Treatment of primary myelofibrosis
Sponsor: CTI Life Sciences Ltd
Highland House, Basingstoke Road, Spencers Wood, Reading, Berkshire RG7 1NT, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
27/08/2010 Orphan designation EMA/OD/019/10 (2010)5966 of 25/08/2010
23/03/2015 Transfer of orphan designation EMA/OD/019/10/T/01 (2015)2043 of 19/03/2015
28/05/2015 Change of name and/or address of sponsor
22/11/2016 Transfer of orphan designation EMA/OD/019/10/T/02 (2016)7582 of 18/11/2016